Christopher Nutting, MD, discusses the results of a randomized phase 3 trial using dysphagia-optimized intensity modulated radiotherapy versus standard IMRT in patients with head and neck cancer.
Christopher Nutting, MD
Advertisement
Articles by Christopher Nutting, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
2
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
3
Beyond SC Daratumumab: Emerging Therapeutic Approaches for Smoldering Myeloma
4
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
5
